Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Current trends in autoimmunity and the nervous system.
Reporting quality of randomized-controlled trials in multiple sclerosis from 2000 to 2015, based on CONSORT statement.
Autophagy-Related Deubiquitinating Enzymes Involved in Health and Disease.
Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis" [J. Neuroimmunol. 290 (2016 Jan. 15) 66-9].
B cells are required for sunlight protection of mice from a CNS-targeted autoimmune attack.
High-Resolution Expression Profiling of Peripheral Blood CD8(+) Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution.
Electrophysiological observations in critically ill Guillain-Barre syndrome.
Favorable outcome of a pregnancy after fampridine exposition during the first month.
Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4.
CellCept (Product Insert)
Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
Leukodystrophies.
Is disability measured by FIM a predictor for successful self-intermittent catheterization in neurological patients?
Statistical estimation of white matter microstructure from conventional MRI.
Preterm white matter brain injury is prevented by early administration of umbilical cord blood cells.
NT-3 promotes proprioceptive axon regeneration when combined with activation of the mTor intrinsic growth pathway but not with reduction of myelin extrinsic inhibitors.
Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Yes.
Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.
CSF B - lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.
The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.
Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.
Cerebrospinal fluid cytokines in Lyme neuroborreliosis.
CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids.
Pages
« first
‹ previous
…
757
758
759
760
761
762
763
764
765
…
next ›
last »